Choosing a Gene-Editing Modality and Delivery Route in 2026
Case Study·Advanced·base-editing, crispr-clinical-translation, gene-therapy-delivery
Make the modality, delivery, and clinical-strategy calls the 2026 evidence supports
Choosing a Gene-Editing Modality and Delivery Route in 2026
Choosing a Gene-Editing Modality and Delivery Route in 2026
You are the R&D strategist for a clinical-stage biotech deciding how to attack a liver-expressed disease gene. The field has multiple viable editing modalities and delivery routes now with real human data. Make the calls the 2026 clinical evidence supports.